Perspective Therapeutics, Inc. - 8-K Filing
Perspective Therapeutics updated its corporate presentation on June 1, 2026. The filing highlights the company's focus on next-generation radiopharmaceuticals targeting solid tumors and melanoma through programs like VMT-⍺-NET, VMT01, and PSV359 in Phase 1/2a trials. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $CATX